Updated Safety Analysis of Fracture Rate With Mandated Bone-Protecting Agents in Phase III EORTC GUCG 1333/PEACE-3 Trial of Enzalutamide ± Radium-223 in mCRPC

Source: 2021 ASCO Virtual Annual Meeting*
Download Slideset
June 4-8, 2021; Online at https://conferences.asco.org/am
Updated safety analysis of EORTC GUCG 1333/PEACE-3 confirms that risk of fractures was well controlled in both treatment arms when patients with mCRPC received BPAs.
Format: Microsoft PowerPoint (.ppt)
File Size: 437 KB
Released: June 15, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Exelixis
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings